Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

NOXOPHARM LIMITED Major Shareholding Notification 2016

Aug 9, 2016

65437_rns_2016-08-09_ea1b2684-2950-4c48-8259-c7b3fc1f9cf6.pdf

Major Shareholding Notification

Open in viewer

Opens in your device viewer

603 Page 1 of 3 15 July 2001

Form 603

Corporations Act 2001

Section 671B

Notice of initial substantial holder

To Company Name/Scheme Noxopharm Limited ACN/ARSN 608 966 123

1. Details of substantial holder (1)

Name Milligene Pty Ltd <The GE + PR Kelly Fam Trust>

ACN/ARSN (if applicable) 607 290 193

The holder became a substantial holder on 9 / August / 2016

2. Details of voting power

The total number of votes attached to all the voting shares in the company or voting interests in the scheme that the substantial holder or an associate (2) had a relevant interest (3) in on the date the substantial holder became a substantial holder are as follows:

Class of securities (4) Number of securities Person's votes (5) Voting power (6)
Ordinary Shares (ORD) 24,345,000 24,345,000 32.38%

3. Details of relevant interests

The nature of the relevant interest the substantial holder or an associate had in the following voting securities on the date the substantial holder became a substantial holder are as follows:

Holder of relevant interest Nature of relevant interest (7) Class and number of securities
Milligene Pty Ltd <The GE +
PR Kelly Fam Trust>
Shareholder ORD 24,150,000
Prue Kelly
Bende Holdings Pty Ltd
Phytose Corporation Limited
<ATF Boundaryone
Superannuation Fund>
Shareholder
Shareholder
Shareholder
ORD 10,000
ORD 10,000
ORD 175,000

4. Details of present registered holders

The persons registered as holders of the securities referred to in paragraph 3 above are as follows:

Holder of relevant
interest
Registered holder of
securities
Person entitled to be
registered asholder(8)
Class and number of securities
Milligene Pty Ltd
<The GE + PR Kelly
Fam Trust>
Milligene Pty Ltd
<The GE + PR Kelly
Fam Trust>
Milligene Pty Ltd
<The GE + PR Kelly
Fam Trust>
ORD 24,150,000
Prue Kelly
Bende Holdings Pty
Ltd
Phytose Corporation
Limited ATF
Boundaryone
Superannuation Fund
Prue Kelly
Bende Holdings Pty
Ltd
Phytose Corporation
Limited ATF
Boundaryone
Superannuation Fund
Prue Kelly
Bende Holdings Pty
Ltd
Phytose Corporation
Limited ATF
Boundaryone
Superannuation Fund
ORD 10,000
ORD 10,000
ORD 175,000

603 Page 2 of 3 15 July 2001

5. Consideration

The consideration paid for each relevant interest referred to in paragraph 3 above, and acquired in the four months prior to the day that the substantial holder became a substantial holder is as follows:

Holder of relevant
interest
Date of acquisition Consideration (9) Consideration (9) Class and number of securities
Cash Non-cash
Milligene Pty Ltd
<The GE + PR Kelly
Fam Trust>
11 November 2015 $2,415
ORD 24,150,000
Prue Kelly
Bende Holdings Pty
Ltd
Phytose Corporation
Limited ATF
Boundaryone
Superannuation Fund
4 August 2016
4 August 2016
4 August 2016
$2,000
$2,000
$35,000


ORD 10,000
ORD 10,000
ORD 175,000

6. Associates

The reasons the persons named in paragraph 3 above are associates of the substantial holder are as follows:

Name and ACN/ARSN (if applicable) Nature of association
Prue Kelly Spouse of Director
Bende Holdings Pty Ltd
Phytose Corporation
Limited ATF Boundaryone
Superannuation Fund
Director related entity
Director related entity

7. Addresses

The addresses of persons named in this form are as follows:

Name Address
All Holdings Suite 715 "Avanti" 1C Burdett Street, Hornsby NSW 2077

Signature

print name
sign here
Gramham Kelly
capacity
Director
date
9/August/2016

DIRECTIONS

  • (1) If there are a number of substantial holders with similar or related relevant interests (eg. a corporation and its related corporations, or the manager and trustee of an equity trust), the names could be included in an annexure to the form. If the relevant interests of a group of persons are essentially similar, they may be referred to throughout the form as a specifically named group if the membership of each group, with the names and addresses of members is clearly set out in paragraph 7 of the form.

  • (2) See the definition of "associate" in section 9 of the Corporations Act 2001.

  • (3) See the definition of "relevant interest" in sections 608 and 671B(7) of the Corporations Act 2001.

  • (4) The voting shares of a company constitute one class unless divided into separate classes.

  • (5) The total number of votes attached to all the voting shares in the company or voting interests in the scheme (if any) that the person or an associate has a relevant interest in.

603 Page 3 of 3 15 July 2001

  • (6) The person's votes divided by the total votes in the body corporate or scheme multiplied by 100.

  • (7) Include details of:

  • (a) any relevant agreement or other circumstances by which the relevant interest was acquired. If subsection 671B(4) applies, a copy of any document setting out the terms of any relevant agreement, and a statement by the person giving full and accurate details of any contract, scheme or arrangement, must accompany this form, together with a written statement certifying this contract, scheme or arrangement; and

  • (b) any qualification of the power of a person to exercise, control the exercise of, or influence the exercise of, the voting powers or disposal of the securities to which the relevant interest relates (indicating clearly the particular securities to which the qualification applies).

  • See the definition of "relevant agreement" in section 9 of the Corporations Act 2001.

  • (8) If the substantial holder is unable to determine the identity of the person ( eg. if the relevant interest arises because of an option) write "unknown".

  • (9) Details of the consideration must include any and all benefits, money and other, that any person from whom a relevant interest was acquired has, or may, become entitled to receive in relation to that acquisition. Details must be included even if the benefit is conditional on the happening or not of a contingency. Details must be included of any benefit paid on behalf of the substantial holder or its associate in relation to the acquisitions, even if they are not paid directly to the person from whom the relevant interest was acquired.